Many academic researchers and pharmaceutical companies have identified new Alzheimer's drug therapy candidates, but lack the funding to move them into human testing. At the same time, few funding sources support early-phase clinical drug trials. As a result, too many promising studies stall out early in the discovery process.
More...
Linear Mode
